These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33492633)

  • 1. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Mid-Cycle Communications.
    Hoffman RD; Beattie SD; Camp JR; Fuhs JV
    Ther Innov Regul Sci; 2023 Jul; 57(4):689-701. PubMed ID: 37014601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
    Chahal HS; Mukherjee S; Sigelman DW; Temple R
    JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Evaluation of US Food and Drug Administration's Program to Register HIV Drugs for Use in Resource-Constrained Settings.
    Chahal HS; Koukounas K; Capella P; Presto R; Murray JS; Shimer M; Riley K; Valdez ML
    JAMA Netw Open; 2019 Nov; 2(11):e1915787. PubMed ID: 31747034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronidase (Vitrase)--ISTA: hyaluronidase--ISTA pharmaceuticals.
    Drugs R D; 2003; 4(3):194-7. PubMed ID: 12757408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities.
    Feng C; Virparia R; Mui ET
    Ther Innov Regul Sci; 2021 Jul; 55(4):881-888. PubMed ID: 33913098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies.
    Fermaglich LJ; Chen R; Kim CY; Chuh EE; Thomas T; Shetty D; Lee J; Young J; Fan Y
    Ther Innov Regul Sci; 2019 Jan; 53(1):81-85. PubMed ID: 29719976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new drug approvals of 1987, 1988, and 1989: trends in drug development.
    Kaitin KI; DiCerbo PA; Lasagna L
    J Clin Pharmacol; 1991 Feb; 31(2):116-22. PubMed ID: 2010558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.